Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy

C. Venkata S Ram, Domingo Gonzalez, Padmakar V Kulkarni, Prabha Sunderajan, James Corbett, Anne Taylor, Nannepaga Y. Zachariah, Norman M Kaplan

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Left ventricular hypertrophy is a common consequence of chronic hypertension. Although the hypertrophic response can be considered an adaptive mechanism in the initial stages, its progression is associated with increased cardiovascular morbidity and mortality rates. Therefore, reversal of left ventricular hypertrophy may provide considerable clinical benefits to hypertensive patients. Although treatment of hypertension per se is important, blood pressure alone may not explain the course of the hypertrophic process. Not all antihypertensive drugs cause a reversal of hypertrophy, though they may produce equal effects on blood pressure. Factors other than the severity of blood pressure may play a role in the genesis of left ventricular hypertrophy. Adrenergic inhibitors cause its regression, whereas direct vasodilators may promote progression. In this study, therapy with the alpha-adrenergic inhibitor prazosin resulted in significant regression of left ventricular hypertrophy in a group of patients with moderate-to-severe hypertension. This study utilized a new technique-[123I]phenylpen-tadecanoic acid myocardioscintigraphy-to measure the left ventricular mass. In this study, it was shown that monotherapy with prazosin produced significant relative reductions in systolic and diastolic blood pressure, along with significant reductions in left ventricular mass.

Original languageEnglish (US)
Pages (from-to)66-69
Number of pages4
JournalThe American journal of medicine
Volume86
Issue number1 SUPPL. 2
DOIs
StatePublished - Jan 23 1989

Fingerprint

Prazosin
Left Ventricular Hypertrophy
Blood Pressure
Hypertension
Adrenergic Agents
Therapeutics
Vasodilator Agents
Hypertrophy
Antihypertensive Agents
Morbidity
Acids
Mortality

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy. / Ram, C. Venkata S; Gonzalez, Domingo; Kulkarni, Padmakar V; Sunderajan, Prabha; Corbett, James; Taylor, Anne; Zachariah, Nannepaga Y.; Kaplan, Norman M.

In: The American journal of medicine, Vol. 86, No. 1 SUPPL. 2, 23.01.1989, p. 66-69.

Research output: Contribution to journalArticle

Ram, C. Venkata S ; Gonzalez, Domingo ; Kulkarni, Padmakar V ; Sunderajan, Prabha ; Corbett, James ; Taylor, Anne ; Zachariah, Nannepaga Y. ; Kaplan, Norman M. / Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy. In: The American journal of medicine. 1989 ; Vol. 86, No. 1 SUPPL. 2. pp. 66-69.
@article{c56c7e3838744399984b5b2b03e8c59a,
title = "Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy",
abstract = "Left ventricular hypertrophy is a common consequence of chronic hypertension. Although the hypertrophic response can be considered an adaptive mechanism in the initial stages, its progression is associated with increased cardiovascular morbidity and mortality rates. Therefore, reversal of left ventricular hypertrophy may provide considerable clinical benefits to hypertensive patients. Although treatment of hypertension per se is important, blood pressure alone may not explain the course of the hypertrophic process. Not all antihypertensive drugs cause a reversal of hypertrophy, though they may produce equal effects on blood pressure. Factors other than the severity of blood pressure may play a role in the genesis of left ventricular hypertrophy. Adrenergic inhibitors cause its regression, whereas direct vasodilators may promote progression. In this study, therapy with the alpha-adrenergic inhibitor prazosin resulted in significant regression of left ventricular hypertrophy in a group of patients with moderate-to-severe hypertension. This study utilized a new technique-[123I]phenylpen-tadecanoic acid myocardioscintigraphy-to measure the left ventricular mass. In this study, it was shown that monotherapy with prazosin produced significant relative reductions in systolic and diastolic blood pressure, along with significant reductions in left ventricular mass.",
author = "Ram, {C. Venkata S} and Domingo Gonzalez and Kulkarni, {Padmakar V} and Prabha Sunderajan and James Corbett and Anne Taylor and Zachariah, {Nannepaga Y.} and Kaplan, {Norman M}",
year = "1989",
month = "1",
day = "23",
doi = "10.1016/0002-9343(89)90134-4",
language = "English (US)",
volume = "86",
pages = "66--69",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "1 SUPPL. 2",

}

TY - JOUR

T1 - Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy

AU - Ram, C. Venkata S

AU - Gonzalez, Domingo

AU - Kulkarni, Padmakar V

AU - Sunderajan, Prabha

AU - Corbett, James

AU - Taylor, Anne

AU - Zachariah, Nannepaga Y.

AU - Kaplan, Norman M

PY - 1989/1/23

Y1 - 1989/1/23

N2 - Left ventricular hypertrophy is a common consequence of chronic hypertension. Although the hypertrophic response can be considered an adaptive mechanism in the initial stages, its progression is associated with increased cardiovascular morbidity and mortality rates. Therefore, reversal of left ventricular hypertrophy may provide considerable clinical benefits to hypertensive patients. Although treatment of hypertension per se is important, blood pressure alone may not explain the course of the hypertrophic process. Not all antihypertensive drugs cause a reversal of hypertrophy, though they may produce equal effects on blood pressure. Factors other than the severity of blood pressure may play a role in the genesis of left ventricular hypertrophy. Adrenergic inhibitors cause its regression, whereas direct vasodilators may promote progression. In this study, therapy with the alpha-adrenergic inhibitor prazosin resulted in significant regression of left ventricular hypertrophy in a group of patients with moderate-to-severe hypertension. This study utilized a new technique-[123I]phenylpen-tadecanoic acid myocardioscintigraphy-to measure the left ventricular mass. In this study, it was shown that monotherapy with prazosin produced significant relative reductions in systolic and diastolic blood pressure, along with significant reductions in left ventricular mass.

AB - Left ventricular hypertrophy is a common consequence of chronic hypertension. Although the hypertrophic response can be considered an adaptive mechanism in the initial stages, its progression is associated with increased cardiovascular morbidity and mortality rates. Therefore, reversal of left ventricular hypertrophy may provide considerable clinical benefits to hypertensive patients. Although treatment of hypertension per se is important, blood pressure alone may not explain the course of the hypertrophic process. Not all antihypertensive drugs cause a reversal of hypertrophy, though they may produce equal effects on blood pressure. Factors other than the severity of blood pressure may play a role in the genesis of left ventricular hypertrophy. Adrenergic inhibitors cause its regression, whereas direct vasodilators may promote progression. In this study, therapy with the alpha-adrenergic inhibitor prazosin resulted in significant regression of left ventricular hypertrophy in a group of patients with moderate-to-severe hypertension. This study utilized a new technique-[123I]phenylpen-tadecanoic acid myocardioscintigraphy-to measure the left ventricular mass. In this study, it was shown that monotherapy with prazosin produced significant relative reductions in systolic and diastolic blood pressure, along with significant reductions in left ventricular mass.

UR - http://www.scopus.com/inward/record.url?scp=45349110425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45349110425&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(89)90134-4

DO - 10.1016/0002-9343(89)90134-4

M3 - Article

C2 - 2521543

AN - SCOPUS:45349110425

VL - 86

SP - 66

EP - 69

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 1 SUPPL. 2

ER -